Novel Therapy for Treating Fungal Infection of the Cornea

Tech ID: 29174 / UC Case 2017-580-0

Brief Description

Fungal keratitis is an infection of the cornea caused by pathogenic fungi that is challenging to treat. This therapy is a novel topical application of a commercially-available malarial drug to treat fungal keratitis with fewer side effects than current treatments.

Full Description

Fungal keratitis is a rare, yet serious, corneal disease that remains a challenge to treat. Individuals can quickly develop a corneal infection from exposure to different fungi (Fusarium, Aspergillus, or Candida) with an eye injury or contact lens use. Resulting corneal infections, if left untreated, could lead to irreversible blindness. Patients with fungal keratitis are typically treated with anti-fungal eye drops and oral anti-fungal medications including: topical natamycin, voriconazole, systemic voriconazole, amphotericin B. These treatments, however, produce little efficacy and can produce toxic side effects in the kidneys. UCI researchers discovered a novel application of atovaquone (historically used as a systemic malarial treatment) which can be used topically to treat corneal fungal keratitis. Atovaquone in therapeutic doses showed significant anti-fungal growth of Aspergillus and Fusarium and furthermore, atovaquone eye drops inhibited fungal growth in a murine model of corneal infection. Moveover, the researchers elucidated two mechanisms of action by atovaquone, which enables further exploiting the anti-fungal activity of atovaquone to directly kill and inhibit growth of filamentous fungi.

Suggested uses

Novel topical treatment for fungal corneal infections to prevent visual impairment

Advantages

· Effective anti-fungal activity (about 10-fold reduction of Aspergillus and Fusarium species)

· Inexpensive topical formulation

· Fewer side effects than current treatments

· Monotherapy or combinatorial treatment with other anti-fungal agents

Patent Status

Patent Pending

State Of Development

  • Demonstrated efficacy of topical atovaquone in reducing Aspergillus and Fusarium growth in vitro and in vivo murine model of
  • Perspective in vivo studies in a rabbit model of corneal infection

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Other Information

Categorized As

  • AN INTEGRAL PART OF
  • Institute for Innovation Logo
  • Institute for Innovation Logo

University of California, Irvine Invention Transfer Group
5141 California Avenue, Suite 200, Irvine,CA 92697-7700
Tel: 949.824.2683 | Fax: 949.824.3880
www.ota.uci.edu | ota@uci.edu

© 2018, The Regents of the University of California
Terms of use | Privacy Notice